Wuxi PharmaTech Obtains Humane Animal Treatment Accreditation For Toxicology Facility In Eastern China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of Wuxi PharmaTech, China's dominant contract research organization, said the Shanghai-based outfit is on track to begin offering GLP-compliant drug safety testing services by the second half of the year at its new, leading-edge toxicology center
You may also be interested in...
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
BEIJING - Just days after disclosing that a newly launched drug safety testing center had been accredited by a U.S. group, leading Chinese contract research organization Wuxi PharmaTech signed a toxicology deal with Johnson & Johnson Pharmaceutical Research & Development